Workflow
Biopharmaceuticals
icon
搜索文档
NuCana Announces ADS Ratio Change
Globenewswire· 2025-08-02 04:05
EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company’s previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Ef ...
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Globenewswire· 2025-08-02 03:57
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen has become a recognized name ...
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Globenewswire· 2025-08-02 03:30
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC. WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development progra ...
Regeneron(REGN) - 2025 Q2 - Earnings Call Transcript
2025-08-01 21:32
Regeneron Pharmaceuticals (REGN) Q2 2025 Earnings Call August 01, 2025 08:30 AM ET Company ParticipantsRyan Crowe - SVP - IR & Strategic AnalysisLeonard Schleifer - Board co-Chair, President & CEOGeorge Yancopoulos - Board co-Chair, President & Chief Scientific OfficerMarion McCourt - Executive Vice President of CommercialChris Fenimore - EVP, Finance and CFOChris Schott - Managing DirectorGeoff Meacham - Managing DirectorCory Kasimov - Senior Managing DirectorAkash Tewari - Global Head - Biopharmaceutical ...
Regeneron(REGN) - 2025 Q2 - Earnings Call Transcript
2025-08-01 21:30
Regeneron Pharmaceuticals (REGN) Q2 2025 Earnings Call August 01, 2025 08:30 AM ET Speaker0Welcome to the Regeneron Pharmaceuticals Second Quarter twenty twenty five Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded.I will now turn the call over to Ryan Crow, Senior Vice President, Investor Relations. ...
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
GlobeNewswire News Room· 2025-08-01 18:50
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, Chris Mutz, Head of Rare Disease, and Mary Pao, M.D., Ph.D., Chief Medical Officer, will host a conference call to discu ...
Oculis Upsized Loan Facility to Access up to CHF 100 million
GlobeNewswire News Room· 2025-08-01 16:00
贷款协议修订 - Oculis Holding AG与BlackRock管理的基金和账户修订了贷款协议 提供7500万瑞士法郎的借款能力 并可增至1亿瑞士法郎 [1][2] - 贷款分为三部分 每部分2500万瑞士法郎 另可提供最高2500万瑞士法郎的额外贷款 签署时未提取任何金额 [2] 资金用途与里程碑 - 新增资金将支持公司在2025年下半年至2026年期间的关键临床里程碑 包括与FDA就Privosegtor(OCS-05)三种适应症进行监管讨论 [3] - 计划在2025年下半年启动Licaminlimab(OCS-02)治疗干眼症的2/3期试验 2026年上半年启动Privosegtor治疗急性视神经炎的2/3期试验 [3] - OCS-01的3期DIAMOND试验顶线结果预计在2026年第二季度公布 若结果积极将在2026年下半年提交首个新药申请 [3] 公司财务状况 - 当前强劲的现金状况可支持运营至2028年初 贷款安排进一步增强了财务灵活性 [4] - 首席执行官表示贷款协议修订有助于确保公司未来的财务和运营实力 [4] 产品管线概述 - OCS-01是处于关键注册研究的滴眼液 有望成为首个治疗糖尿病黄斑水肿的非侵入性局部疗法 [5] - Privosegtor(OCS-05)是首创的神经保护候选药物 处于2期研究阶段 具有广泛的神经眼科和神经系统疾病应用潜力 [5] - Licaminlimab(OCS-02)是首创的局部抗TNFα药物 采用基因型方法开发 用于干眼病的个性化治疗 [5]
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
Globenewswire· 2025-08-01 07:30
文章核心观点 - 生物制药公司MediciNova宣布达成一项最高3000万美元的备用股权购买协议(SEPA),可在36个月内出售普通股,交易所得将用于推进研发项目和一般公司活动 [1][2] 协议内容 - 公司有权但无义务在个别交易中出售普通股,每次出售上限为交易日前五天公司普通股日均交易量的100% [2] - 股票将无额外认股权证发行,以市场价格的97%出售给Yorkville Advisors Global LP管理的一只或多只投资基金 [2] 公司表态 - 公司当前现金状况可维持运营和资助现有项目,SEPA提供额外资金灵活性,支持研发、业务拓展和战略机遇,且不发行认股权证可利用有利市场条件,协议证明公司市场地位和临床进展 [3] SEPA介绍 - SEPA是具有法律约束力的安排,允许上市公司在最多三年内按自身意愿向投资者出售新股募资,投资者承诺按预定折扣购买一定数量股票,受交易量限制、公司设定的最低价格和转售登记等条件约束,提供灵活、非强制性股权融资途径 [4] 公司介绍 - MediciNova是临床阶段生物制药公司,专注美国市场,当前战略聚焦MN - 166治疗神经及其他疾病、MN - 001治疗纤维化及其他代谢疾病,通过多种方式推进产品线临床开发 [5] 投资者联系方式 - 首席商务官David H. Crean,邮箱info@medicinova.com [8] 市场价格定义 - 市场价格是投资者收到预付款通知后的连续三个交易日内普通股的最低每日成交量加权平均价格(VWAP) [8]
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Globenewswire· 2025-08-01 04:15
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and developmentRADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug developm ...
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
Globenewswire· 2025-08-01 04:05
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full m ...